Definium: 'Strong Buy' Maintained On Several Anticipated 2026 Milestones [Seeking Alpha]
Definium Therapeutics, Inc. - Common Shares (DFTX)
Company Research
Source: Seeking Alpha
DFTX expects three pivotal data readouts in 2026 from phase 3 trials of DT120 ODT for GAD and MDD, plus phase 2a data for DT402 in ASD. DT402 targets a large unmet need in adult ASD, leveraging a differentiated R(-)-MDMA profile with prior phase 1 safety validation. With $411.6M cash and no near-term funding needs, DFTX is well-positioned to execute through multiple clinical milestones into 2028. Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » Kintarapong/iStock via Getty Images The last time I spoke about Definium Therapeutics, Inc. ( DFTX ) it was with a Seeking Alpha article entitled "Mind Medicine: Two Pathways Created From One Pipeline Clinical Candidate." In that article, I mentioned two specific programs that More on my IG service This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marke
Show less
Read more
Impact Snapshot
Event Time:
DFTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DFTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DFTX alerts
High impacting Definium Therapeutics, Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
DFTX
News
- Is It Too Late To Consider Definium Therapeutics (DFTX) After Its Strong 1 Year Run? [Yahoo! Finance]Yahoo! Finance
- Definium Therapeutics Teases 3 Phase III DT120 Readouts in 2026, Starting Late Q2 MDD Data [Yahoo! Finance]Yahoo! Finance
- Definium Therapeutics (DFTX) was given a new $30.00 price target by Stifel Nicolaus.MarketBeat
- Definium Therapeutics (DFTX) was given a new $38.00 price target by Canaccord Genuity Group Inc..MarketBeat
- Definium Therapeutics (DFTX) is now covered by Piper Sandler. They set an "overweight" rating and a $49.00 price target on the stock.MarketBeat
DFTX
Earnings
- 2/26/26 - Miss
DFTX
Sec Filings
- 3/26/26 - Form 4
- 3/26/26 - Form 4
- 3/26/26 - Form 4
- DFTX's page on the SEC website